| Not Yet Recruiting | Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded t NCT07437963 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Suspended | Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Youn NCT04539366 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or R NCT04751383 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and You NCT04500548 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tum NCT04530487 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With NCT03794349 | Children's Oncology Group | Phase 2 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and H NCT03209869 | University of Wisconsin, Madison | Phase 1 |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lympho NCT03213691 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma NCT03057626 | Children's Oncology Group | — |
| Completed | Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma NCT02641314 | University of Cologne | Phase 2 |
| Completed | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma NCT02452554 | Children's Oncology Group | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Unknown | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteo NCT02173093 | University of Virginia | Phase 1 / Phase 2 |
| Withdrawn | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02011126 | Children's Oncology Group | Phase 2 |
| Terminated | Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma NCT02163356 | South Plains Oncology Consortium | Phase 1 |
| Completed | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02095132 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT01606878 | Children's Oncology Group | Phase 1 |
| Completed | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With R NCT01767194 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recu NCT01711554 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Completed | Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblast NCT01334515 | Children's Oncology Group | Phase 2 |
| Completed | Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma NCT01358617 | Children's Oncology Group | — |
| Completed | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01154816 | Children's Oncology Group | Phase 2 |
| Completed | Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma NCT01208454 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Completed | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymp NCT00939770 | Children's Oncology Group | Phase 1 / Phase 2 |
| Completed | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors NCT00831844 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Tran NCT00567567 | Children's Oncology Group | Phase 3 |
| Completed | Study of DNA in Blood Samples From Patients With Neuroblastoma NCT00898391 | Children's Oncology Group | — |
| Completed | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagn NCT00638898 | City of Hope Medical Center | Phase 1 |
| Completed | ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment NCT00436852 | Children's Oncology Group | Phase 2 |
| Completed | Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions NCT00436696 | Children's Oncology Group | — |
| Completed | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601 | Roswell Park Cancer Institute | N/A |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | Ixabepilone in Treating Young Patients With Refractory Solid Tumors NCT00331643 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Tr NCT00309907 | Children's Oncology Group | Phase 2 |
| Completed | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, NCT00217412 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas NCT00101270 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatme NCT00091182 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors NCT00093821 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors NCT00077454 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or NCT00075634 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma NCT00053326 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma NCT00054405 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neurob NCT00053950 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood NCT00030667 | National Cancer Institute (NCI) | Phase 2 |
| Completed | R(+)XK469 in Treating Patients With Advanced Neuroblastoma NCT00028522 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Trea NCT00026312 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas NCT00012181 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma NCT00005576 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Irinotecan in Treating Children With Refractory Solid Tumors NCT00004078 | Children's Oncology Group | Phase 2 |
| No Longer Available | Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma NCT02075177 | South Plains Oncology Consortium | — |